Assess whether labeling language overclaims the evidence from 505(b)(2)

Situation

The desk packet is 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings. Labeling negotiator in a biologics company planning a biosimilar pathway has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences FDA Response and Labeling file.

Decision

Labeling negotiator in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after an AdCom briefing document that overstates subgroup findings.
• Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after an AdCom briefing document that overstates subgroup findings for labeling negotiator.
• Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after an AdCom briefing document that overstates subgroup findings.
• Refuse a Pharma & Life Sciences close: labeling negotiator does not have the page labeling language overclaims the turns on in 505(b)(2) literature-to-product bridge table.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on labeling language overclaims the.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim labeling negotiator would keep.
• For this Pharma & Life Sciences FDA Response and Labeling file, read 505(b)(2) literature-to-product bridge table against an AdCom briefing document that overstates subgroup findings and write the one fact that would move labeling language overclaims the for labeling negotiator.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings). If 505(b)(2) literature-to-product bridge table cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent pages a biologics company planning a biosimilar pathway does not have.